With COVID-19 forcing many rheumatologists to conduct consultations online, in Part 3 of our ACR 2020 highlights, Peter C Taylor (University of Oxford, Oxford, UK) summarises the investigation into the PT-CDAI, a patient-reported clinical disease activity tool that could help in target-based care in the era of telemedicine.
The study entitled ‘Can a Clinical Disease Activity Index Based on Patient-Reported Joint Counts (PT-CDAI) Be Used to Inform Target-Based Care in Telemedicine?’ was presented at ACR Convergence 2020.
Disclosures: Peter C Taylor reports receiving: Research grants from Celgene, Galapagos, Gilead and Lilly; and consultation fees from AbbVie, BMS, Biogen, Fresenius, Galapagos, Gilead, GlaxoSmithKline, Janssen, Lilly, Nordic Pharma, Pfizer, Roche, Sanofi, and UCB.
Support: Interview and filming supported by Touch Medical Media Ltd.
Filmed in coverage of virtual ACR Convergence 2020.
Share this Video
Related Videos In Rheumatic Diseases
Nicholas Harvey, WCO21: The Royal Osteoporosis Society Research Roadmap
touchIMMUNOLOGY joins Professor Nicholas Harvey (University of Southampton, UK) at WCO21 to discuss the aims and hopes of the Royal Osteoporosis Society’s Research Roadmap initiative. Questions 1. What are the current unmet needs in osteoporosis and bone research? (00:27-01:26) 2. Please can you provide a short summary of the main aims of the Osteoporosis and […]
Emma Clark, WCO21: Novel Technologies for Skeletal Assessment
touchIMMUNOLOGY joins Professor Emma Clark (University of Bristol, UK) at WCO21 to discuss the current limitations of osteoporosis diagnosis and the latest novel technologies for skeletal assessment. Questions 1. Why is the diagnosis of osteoporosis so challenging? (00:16-02:13) 2. What are the strengths and limitations of currently available tools and services to diagnose osteoporosis? (02:13-04:28) […]
Philip Conaghan, WCO21: Tanezumab in the Treatment of Patients with Moderate-to-severe Osteoarthritis
touchIMMUNOLOGY joins Professor Philip Conaghan (University of Leeds, UK) at WCO21 to discuss improvements in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) and use of tanezumab in the treatment of patients with moderate-to-severe osteoarthritis. Questions 1. What is the rationale for the use of tanezumab in the treatment of patients with moderate-to-severe osteoarthritis? […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!